Targeting ANXA1 abrogates Treg-mediated immune suppression in triple-negative breast cancer.

Fang BaiPeng ZhangYipeng FuHongliang ChenMingdi ZhangQianru HuangDan LiBin LiKejin Wu

Published in: Journal for immunotherapy of cancer (2021)

ANXA1 can enhance the function of Treg cells and reduce the survival rate of patients with breast cancer. Targeting ANXA1 can reduce Treg cell function and shrink breast tumors.

Keyphrases

induced apoptosis
cancer therapy
cell cycle arrest
signaling pathway
oxidative stress
cell death
endoplasmic reticulum stress
drug delivery